Alzheimer disease: Modeling an Aβ-centered biological network

Molecular Psychiatry

Volumn 21, Issue 7, 2016, Pages 861-871

  Campion, D ^a,b,c,d   Pottier, C ^a,d   Nicolas, G ^a,b,d,e   Le Guennec, K ^a,d   Rovelet Lecrux, A ^a,d  

^a UNIVERSITY OF ROUEN   (France)

^b National Reference Center for Young Alzheimer Patients (CNR MAJ)   (France)

^c Rouvray Psychiatric Hospital   (France)

^d Normandie University   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; BETA SECRETASE; CHOLESTEROL; GAMMA SECRETASE; PROTEASOME; TAU PROTEIN; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; AUTOPHAGY; BLOOD BRAIN BARRIER; CELL FUNCTION; ENDOPLASMIC RETICULUM; ENDOSOME; FEASIBILITY STUDY; HERITABILITY; HUMAN; LIPID HOMEOSTASIS; MICROGLIA; MITOCHONDRIAL TOXICITY; NERVE FIBER TRANSPORT; NEXT GENERATION SEQUENCING; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REVIEW; SECRETORY PATHWAY; ANIMAL; GENE REGULATORY NETWORK; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; NUCLEIC ACID DATABASE; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DATABASES, NUCLEIC ACID; GENE REGULATORY NETWORKS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS;

EID: 84961711869     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2016.38     Document Type: Review

References (179)

1. Rosso SM, Kamphorst W, Ravid R, van Swieten JC. Coexistent tau and amyloid pathology in hereditary frontotemporal dementia with tau mutations. Ann NY Acad Sci 2000; 920: 115-119
2. Ishida C, Kobayashi K, Kitamura T, Ujike H, Iwasa K, Yamada M. Frontotemporal dementia with parkinsonism linked to chromosome 17 with the MAPT R406W mutation presenting with a broad distribution of abundant senile plaques. Neuropathology 2015; 35: 75-82
3. Hurtado DE, Molina-Porcel L, Iba M, Aboagye AK, Paul SM, Trojanowski JQ, et al. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol 2010; 177: 1977-1988
4. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184-185
5. Walsh DM, Selkoe DJ. A beta oligomers-A decade of discovery. J Neurochem 2007; 101: 1172-1184
6. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259
7. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992; 42: 631-639
8. Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 2002; 59: 398-407
9. Ittner LM, Gotz J. Amyloid-beta and tau-A toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011; 12: 65-72
10. Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 2014; 71: 505-508
11. Duyckaerts C. Neurodegenerative lesions: seeding and spreading. Rev Neurol 2013; 169: 825-833
12. Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci 2015; 18: 800-806
13. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011; 16: 903-907
14. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-Analysis of 74, 046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45: 1452-1458
15. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. New Engl J Med 2013; 368: 107-116
16. Wu G, Zhi D. Pathway-based approaches for sequencing-based genome-wide association studies. Genet Epidemiol 2013; 37: 478-494
17. Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, et al. The neuronal sortilinrelated receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007; 39: 168-177
18. Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature 2014; 515: 216-221
19. Rovelet-Lecrux A, Charbonnier C, Wallon D, Nicolas G, Seaman MN, Pottier C, et al. De novo deleterious genetic variations target a biological network centered on Abeta peptide in early-onset Alzheimer disease. Mol Psychiatry 2015; 20: 1046-1056
20. Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2012; 2: a006270
21. Claeysen S, Cochet M, Donneger R, Dumuis A, Bockaert J, Giannoni P. Alzheimer culprits: cellular crossroads and interplay. Cell Signal 2012; 24: 1831-1840
22. De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 2010; 90: 465-494
23. Hoshino T, Nakaya T, Araki W, Suzuki K, Suzuki T, Mizushima T. Endoplasmic reticulum chaperones inhibit the production of amyloid-beta peptides. Biochem J 2007; 402: 581-589
24. Huttunen HJ, Guenette SY, Peach C, Greco C, Xia W, Kim DY, et al. HtrA2 regulates beta-Amyloid precursor protein (APP) metabolism through endoplasmic reticulum-Associated degradation. J Biol Chem 2007; 282: 28285-28295
25. Kaneko M, Koike H, Saito R, Kitamura Y, Okuma Y, Nomura Y. Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-beta generation. J Neurosci 2010; 30: 3924-3932
26. Kumar P, Ambasta RK, Veereshwarayya V, Rosen KM, Kosik KS, Band H, et al. CHIP and HSPs interact with beta-APP in a proteasome-dependent manner and influence Abeta metabolism. Hum Mol Genet 2007; 16: 848-864
27. Ullrich S, Munch A, Neumann S, Kremmer E, Tatzelt J, Lichtenthaler SF. The novel membrane protein TMEM59 modulates complex glycosylation, cell surface expression, and secretion of the amyloid precursor protein. J Biol Chem 2010; 285: 20664-20674
28. Parisiadou L, Bethani I, Michaki V, Krousti K, Rapti G, Efthimiopoulos S. Homer2 and Homer3 interact with amyloid precursor protein and inhibit Abeta production. Neurobiol Dis 2008; 30: 353-364
29. Zhou X, Hu X, He W, Tang X, Shi Q, Zhang Z, et al. Interaction between amyloid precursor protein and Nogo receptors regulates amyloid deposition. FASEB J 2011; 25: 3146-3156
30. Wang J, Shan C, Cao W, Zhang C, Teng J, Chen J. SCG10 promotes nonamyloidogenic processing of amyloid precursor protein by facilitating its trafficking to the cell surface. Hum Mol Genet 2013; 22: 4888-4900
31. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005; 307: 1282-1288
32. Steuble M, Diep TM, Schatzle P, Ludwig A, Tagaya M, Kunz B, et al. Calsyntenin-1 shelters APP from proteolytic processing during anterograde axonal transport. Biol Open 2012; 1: 761-774
33. Yang GZ, Yang M, Lim Y, Lu JJ, Wang TH, Qi JG, et al. Huntingtin associated protein 1 regulates trafficking of the amyloid precursor protein and modulates amyloid beta levels in neurons. J Neurochem 2012; 122: 1010-1022
34. Sisodia SS. Beta-Amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci USA 1992; 89: 6075-6079
35. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, et al. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 2010; 29: 3020-3032
36. Suh J, Choi SH, Romano DM, Gannon MA, Lesinski AN, Kim DY, et al. ADAM10 missense mutations potentiate beta-Amyloid accumulation by impairing prodomain chaperone function. Neuron 2013; 80: 385-401
37. Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 suppresses beta-Amyloid production by activating the alpha-secretase gene ADAM10. Cell 2010; 142: 320-332
38. Xu D, Sharma C, Hemler ME. Tetraspanin12 regulates ADAM10-dependent cleavage of amyloid precursor protein. FASEB J 2009; 23: 3674-3681
39. Ohno M, Hiraoka Y, Lichtenthaler SF, Nishi K, Saijo S, Matsuoka T, et al. Nardilysin prevents amyloid plaque formation by enhancing alpha-secretase activity in an Alzheimer's disease mouse model. Neurobiol Aging 2014; 35: 213-222
40. Marcello E, Gardoni F, Mauceri D, Romorini S, Jeromin A, Epis R, et al. Synapseassociated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity. J Neurosci 2007; 27: 1682-1691
41. Amour A, Knight CG, Webster A, Slocombe PM, Stephens PE, Knauper V, et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 2000; 473: 275-279
42. Vingtdeux V, Marambaud P. Identification and biology of alpha-secretase. J Neurochem 2012; 120: 34-45
43. Capell A, Steiner H, Willem M, Kaiser H, Meyer C, Walter J, et al. Maturation and pro-peptide cleavage of beta-secretase. J Biol Chem 2000; 275: 30849-30854
44. He W, Lu Y, Qahwash I, Hu XY, Chang A, Yan R. Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation. Nat Med 2004; 10: 959-965
45. Ho A, Sudhof TC. Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage. Proc Natl Acad Sci USA 2004; 101: 2548-2553
46. Matsuda S, Giliberto L, Matsuda Y, McGowan EM, D'Adamio L. BRI2 inhibits amyloid beta-peptide precursor protein processing by interfering with the docking of secretases to the substrate. J Neurosci 2008; 28: 8668-8676
47. Matsuda S, Matsuda Y, D'Adamio L. BRI3 inhibits amyloid precursor protein processing in a mechanistically distinct manner from its homologue dementia gene BRI2. J Biol Chem 2009; 284: 15815-15825
48. Udayar V, Buggia-Prevot V, Guerreiro RL, Siegel G, Rambabu N, Soohoo AL, et al. A paired RNAi and RabGAP overexpression screen identifies Rab11 as a regulator of beta-Amyloid production. Cell Rep 2013; 5: 1536-1551
49. Sannerud R, Declerck I, Peric A, Raemaekers T, Menendez G, Zhou L, et al. ADP ribosylation factor 6 (ARF6) controls amyloid precursor protein (APP) processing by mediating the endosomal sorting of BACE1. Proc Natl Acad Sci USA 2011; 108: E559-E568
50. Buggia-Prevot V, Fernandez CG, Udayar V, Vetrivel KS, Elie A, Roseman J, et al. A function for EHD family proteins in unidirectional retrograde dendritic transport of BACE1 and Alzheimer's disease Abeta production. Cell Rep 2013; 5: 1552-1563
51. Wahle T, Thal DR, Sastre M, Rentmeister A, Bogdanovic N, Famulok M, et al. GGA1 is expressed in the human brain and affects the generation of amyloid beta-peptide. J Neurosci 2006; 26: 12838-12846
52. Sarajarvi T, Haapasalo A, Viswanathan J, Makinen P, Laitinen M, Soininen H, et al. Down-regulation of seladin-1 increases BACE1 levels and activity through enhanced GGA3 depletion during apoptosis. J Biol Chem 2009; 284: 34433-34443
53. Tesco G, Koh YH, Kang EL, Cameron AN, Das S, Sena-Esteves M, et al. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron 2007; 54: 721-737
54. Zhang M, Deng Y, Luo Y, Zhang S, Zou H, Cai F, et al. Control of BACE1 degradation and APP processing by ubiquitin carboxyl-terminal hydrolase L1. J Neurochem 2012; 120: 1129-1138
55. Gray EH, De Vos KJ, Dingwall C, Perkinton MS, Miller CC. Deficiency of the copper chaperone for superoxide dismutase increases amyloid-beta production. JAD 2010; 21: 1101-1105
56. Li Y, Bohm C, Dodd R, Chen F, Qamar S, Schmitt-Ulms G, et al. Structural biology of presenilin 1 complexes. Mol Neurodegener 2014; 9: 59
57. Wang X, Huang T, Zhao Y, Zheng Q, Thompson RC, Bu G, et al. Sorting nexin 27 regulates Abeta production through modulating gamma-secretase activity. Cell Rep 2014; 9: 1023-1033
58. Cai D, Netzer WJ, Zhong M, Lin Y, Du G, Frohman M, et al. Presenilin-1 uses phospholipase D1 as a negative regulator of beta-Amyloid formation. Proc Natl Acad Sci USA 2006; 103: 1941-1946
59. Park HJ, Shabashvili D, Nekorchuk MD, Shyqyriu E, Jung JI, Ladd TB, et al. Retention in endoplasmic reticulum 1 (RER1) modulates amyloid-beta (Abeta) production by altering trafficking of gamma-secretase and amyloid precursor protein (APP). J Biol Chem 2012; 287: 40629-40640
60. Tanabe C, Maeda T, Zou K, Liu J, Liu S, Nakajima T, et al. The ubiquitin ligase synoviolin up-regulates amyloid beta production by targeting a negative regulator of gamma-secretase, Rer1, for degradation. J Biol Chem 2012; 287: 44203-44211
61. Mitsuishi Y, Hasegawa H, Matsuo A, Araki W, Suzuki T, Tagami S, et al. Human CRB2 inhibits gamma-secretase cleavage of amyloid precursor protein by binding to the presenilin complex. J Biol Chem 2010; 285: 14920-14931
62. Pardossi-Piquard R, Bohm C, Chen F, Kanemoto S, Checler F, Schmitt-Ulms G, et al. TMP21 transmembrane domain regulates gamma-secretase cleavage. J Biol Chem 2009; 284: 28634-28641
63. He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J, et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 2010; 467: 95-98
64. Zhou S, Zhou H, Walian PJ, Jap BK. CD147 is a regulatory subunit of the gammasecretase complex in Alzheimer's disease amyloid beta-peptide production. Proc Natl Acad Sci USA 2005; 102: 7499-7504
65. Wu J, Petralia RS, Kurushima H, Patel H, Jung MY, Volk L, et al. Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent beta-Amyloid generation. Cell 2011; 147: 615-628
66. Thathiah A, Horre K, Snellinx A, Vandewyer E, Huang Y, Ciesielska M, et al. Beta-Arrestin 2 regulates Abeta generation and gamma-secretase activity in Alzheimer's disease. Nat Med 2013; 19: 43-49
67. Vetrivel KS, Thinakaran G. Membrane rafts in Alzheimer's disease beta-Amyloid production. Biochim Biophys Acta 2010; 1801: 860-867
68. Wollmer M.A. Cholesterol-related genes in Alzheimer's disease. Biochim Biophys Acta 2010; 1801: 762-773
69. Michaki V, Guix FX, Vennekens K, Munck S, Dingwall C, Davis JB, et al. Downregulation of the ATP-binding cassette transporter 2 (Abca2) reduces amyloidbeta production by altering nicastrin maturation and intracellular localization. J Biol Chem 2012; 287: 1100-1111
70. Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 2008; 58: 42-51
71. Cheng H, Vetrivel KS, Gong P, Meckler X, Parent A, Thinakaran G. Mechanisms of disease: new therapeutic strategies for Alzheimer's disease-targeting APP processing in lipid rafts. Nat Clin Pract Neurol 2007; 3: 374-382
72. King GD, Scott Turner R. Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk?. Exp Neurol 2004; 185: 208-219
73. Shahani N, Seshadri S, Jaaro-Peled H, Ishizuka K, Hirota-Tsuyada Y, Wang Q, et al. DISC1 regulates trafficking and processing of APP and Abeta generation. Mol Psychiatry 2015; 20: 874-879
74. Xiao Q, Gil SC, Yan P, Wang Y, Han S, Gonzales E, et al. Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis. J Biol Chem 2012; 287: 21279-21289
75. Carey RM, Balcz BA, Lopez-Coviella I, Slack BE. Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein. BMC Cell Biol 2005; 6: 30
76. Schobel S, Neumann S, Hertweck M, Dislich B, Kuhn PH, Kremmer E, et al. A novel sorting nexin modulates endocytic trafficking and alpha-secretase cleavage of the amyloid precursor protein. J Biol Chem 2008; 283: 14257-14268
77. Small SA, Gandy S. Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron 2006; 52: 15-31
78. Reitz C. The role of the retromer complex in aging-related neurodegeneration: a molecular and genomic review. Mol Genet Genomics 2015; 290: 413-427
79. Muhammad A, Flores I, Zhang H, Yu R, Staniszewski A, Planel E, et al. Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc Natl Acad Sci USA 2008; 105: 7327-7332
80. Pottier C, Hannequin D, Coutant S, Rovelet-Lecrux A, Wallon D, Rousseau S, et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry 2012; 17: 875-879
81. Nicolas G, Charbonnier C, Wallon D, Quenez O, Bellenguez C, Grenier-Boley B, et al. SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. Mol Psychiatry 2015. doi: 10.1038/mp.2015.121
82. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 2004; 41: 193-202
83. Bettens K, Brouwers N, Engelborghs S, Lambert JC, Rogaeva E, Vandenberghe R, et al. Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Mol Neurodegener 2012; 7: 3
84. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013; 9: 106-118
85. Koldamova R, Fitz NF, Lefterov I. The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration. Biochim Biophys Acta 2010; 1801: 824-830
86. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 2009; 8: 16-30
87. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2007; 27: 909-918
88. Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, et al. Neuronal clearance of amyloid-beta by endocytic receptor LRP1. J Neurosci 2013; 33: 19276-19283
89. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001; 292: 1550-1552
90. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, et al. Insulindegrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998; 273: 32730-32738
91. Liao MC, Van Nostrand WE. Degradation of soluble and fibrillar amyloid betaprotein by matrix metalloproteinase (MT1-MMP) in vitro. Biochemistry 2010; 49: 1127-1136
92. Backstrom JR, Lim GP, Cullen MJ, Tokes ZA. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 1996; 16: 7910-7919
93. Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mizoguchi K, et al. Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. J Neurosci 2007; 27: 8628-8635
94. Pacheco-Quinto J, Eckman EA. Endothelin-converting enzymes degrade intracellular beta-Amyloid produced within the endosomal/lysosomal pathway and autophagosomes. J Biol Chem 2013; 288: 5606-5615
95. Kim MJ, Chae SS, Koh YH, Lee SK, Jo SA. Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain. FASEB J 2010; 24: 4491-4502
96. Abdul-Hay SO, Sahara T, McBride M, Kang D, Leissring M.A. Identification of BACE2 as an avid ss-Amyloid-degrading protease. Mol Neurodegener 2012; 7: 46
97. Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 2006; 51: 703-714
98. Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm 2010; 117: 949-960
99. Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T. Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol 2009; 87: 181-194
100. Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer's disease. Nat Immunol 2015; 16: 229-236
101. Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci 2008; 28: 6333-6341
102. Crehan H, Holton P, Wray S, Pocock J, Guerreiro R, Hardy J. Complement receptor 1 (CR1) and Alzheimer's disease. Immunobiology 2012; 217: 244-250
103. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015; 14: 388-405
104. Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 2015; 160: 1061-1071
105. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006; 442: 920-924
106. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006; 442: 916-919
107. Perry DC, Lehmann M, Yokoyama JS, Karydas A, Lee JJ, Coppola G, et al. Progranulin mutations as risk factors for Alzheimer disease. JAMA Neurol 2013; 70: 774-778
108. Minami SS, Min SW, Krabbe G, Wang C, Zhou Y, Asgarov R, et al. Progranulin protects against amyloid beta deposition and toxicity in Alzheimer's disease mouse models. Nat Med 2014; 20: 1157-1164
109. Steinberg S, Stefansson H, Jonsson T, Johannsdottir H, Ingason A, Helgason H, et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. Nat Genet 2015; 47: 445-447
110. Zhao QF, Yu JT, Tan MS, Tan L. ABCA7 in Alzheimer's disease. Mol Neurobiol 2015; 51: 1008-1016
111. Satoh K, Abe-Dohmae S, Yokoyama S St, George-Hyslop P, Fraser PE. ABCA7 loss of function alters Alzheimer amyloid processing. J Biol Chem 2015; 290: 24152-24165
112. Gregori L, Fuchs C, Figueiredo-Pereira ME, Van Nostrand WE, Goldgaber D. Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J Biol Chem 1995; 270: 19702-19708
113. Burns MP, Zhang L, Rebeck GW, Querfurth HW, Moussa CE. Parkin promotes intracellular Abeta1-42 clearance. Hum Mol Genet 2009; 18: 3206-3216
114. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol 2005; 64: 113-122
115. Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger PA, et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest 2008; 118: 2190-2199
116. Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012; 15: 349-357
117. Hartley DM, Zhao C, Speier AC, Woodard GA, Li S, Li Z, et al. Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are proteaseresistant and inhibit long-term potentiation. J Biol Chem 2008; 283: 16790-16800
118. Schlenzig D, Ronicke R, Cynis H, Ludwig HH, Scheel E, Reymann K, et al. N-terminal pyroglutamate formation of Abeta38 and Abeta40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation. J Neurochem 2012; 121: 774-784
119. Kumar S, Rezaei-Ghaleh N, Terwel D, Thal DR, Richard M, Hoch M, et al. Extracellular phosphorylation of the amyloid beta-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. EMBO J 2011; 30: 2255-2265
120. Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci USA 2002; 99: 7705-7710
121. Evans CG, Wisen S, Gestwicki JE. Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J Biol Chem 2006; 281: 33182-33191
122. Ojha J, Masilamoni G, Dunlap D, Udoff RA, Cashikar AG. Sequestration of toxic oligomers by HspB1 as a cytoprotective mechanism. Mol Cell Biol 2011; 31: 3146-3157
123. Wilhelmus MM, Boelens WC, Otte-Holler I, Kamps B, de Waal RM, Verbeek MM. Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-beta protein toxicity. Brain Res 2006; 1089: 67-78
124. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881-891
125. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000; 97: 2892-2897
126. Cotman SL, Halfter W, Cole GJ. Agrin binds to beta-Amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain. Mol Cell Neurosci 2000; 15: 183-198
127. Castillo GM, Ngo C, Cummings J, Wight TN, Snow AD. Perlecan binds to the beta-Amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J Neurochem 1997; 69: 2452-2465
128. Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci USA 2006; 103: 8628-8633
129. Li X, Zhang X, Ladiwala AR, Du D, Yadav JK, Tessier PM, et al. Mechanisms of transthyretin inhibition of beta-Amyloid aggregation in vitro. J Neurosci 2013; 33: 19423-19433
130. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 2009; 61: 89-104
131. Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J, Riedel NG, et al. Alpha2-macroglobulin associates with beta-Amyloid peptide and prevents fibril formation. Proc Natl Acad Sci USA 1998; 95: 3275-3280
132. Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, Winkler DT, et al. Cystatin C modulates cerebral beta-Amyloidosis. Nat Genet 2007; 39: 1437-1439
133. Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, Klein AM, et al. Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat Genet 2007; 39: 1440-1442
134. Eriksson S, Janciauskiene S, Lannfelt L. Alpha 1-Antichymotrypsin regulates Alzheimer beta-Amyloid peptide fibril formation. Proc Natl Acad Sci USA 1995; 92: 2313-2317
135. Kocherhans S, Madhusudan A, Doehner J, Breu KS, Nitsch RM, Fritschy JM, et al. Reduced reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice. J Neurosci 2010; 30: 9228-9240
136. Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 2011; 70: 532-540
137. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. Beta-Amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 2001; 98: 12245-12250
138. Ono K, Takahashi R, Ikeda T, Yamada M. Cross-seeding effects of amyloid betaprotein and alpha-synuclein. J Neurochem 2012; 122: 883-890
139. Fang YS, Tsai KJ, Chang YJ, Kao P, Woods R, Kuo PH, et al. Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. Nat Commun 2014; 5: 4824
140. Guerrero-Munoz MJ, Castillo-Carranza DL, Krishnamurthy S, Paulucci-Holthauzen AA, Sengupta U, Lasagna-Reeves CA, et al. Amyloid-beta oligomers as a template for secondary amyloidosis in Alzheimer's disease. Neurobiol Dis 2014; 71: 14-23
141. Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, et al. TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol 2014; 127: 811-824
142. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000; 10: 378-384
143. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta-Amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 2002; 99: 6364-6369
144. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007; 316: 750-754
145. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010; 142: 387-397
146. Salter MW, Kalia LV. Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci 2004; 5: 317-328
147. Nisbet RM, Polanco JC, Ittner LM, Gotz J. Tau aggregation and its interplay with amyloid-beta. Acta Neuropathol 2015; 129: 207-220
148. Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric Abeta-induced synaptic dysfunction in Alzheimer's disease. Mol Neurodegener 2014; 9: 48
149. Spires-Jones TL, Friedman T, Pitstick R, Polydoro M, Roe A, Carlson GA, et al. Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy. Neurosci Lett 2014; 562: 63-68
150. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol 2013; 12: 609-622
151. Zempel H, Mandelkow E. Lost after translation: missorting of tau protein and consequences for Alzheimer disease. Trends Neurosci 2014; 37: 721-732
152. Frandemiche ML, De Seranno S, Rush T, Borel E, Elie A, Arnal I, et al. Activitydependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers. J Neurosci 2014; 34: 6084-6097
153. Noble W, Hanger DP, Miller CC, Lovestone S. The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol 2013; 4: 83
154. Iqbal K, Gong CX, Liu F. Hyperphosphorylation-induced tau oligomers. Front Neurol 2013; 4: 112
155. Kins S, Crameri A, Evans DR, Hemmings BA, Nitsch RM, Gotz J. Reduced protein phosphatase 2 A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J Biol Chem 2001; 276: 38193-38200
156. Yu W, Polepalli J, Wagh D, Rajadas J, Malenka R, Lu B. A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Abeta on synapses and dendritic spines. Hum Mol Genet 2012; 21: 1384-1390
157. Mairet-Coello G, Courchet J, Pieraut S, Courchet V, Maximov A, Polleux F. The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Abeta oligomers through Tau phosphorylation. Neuron 2013; 78: 94-108
158. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000; 405: 360-364
159. Hartigan JA, Johnson GV. Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3beta-dependent pathway. J Biol Chem 1999; 274: 21395-21401
160. Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H, et al. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-Amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet 2007; 16: 15-23
161. Del Prete D, Checler F, Chami M. Ryanodine receptors: physiological function and deregulation in Alzheimer disease. Mol Neurodegen 2014; 9: 21
162. Ferreiro E, Oliveira CR, Pereira C. Involvement of endoplasmic reticulum Ca2+ release through ryanodine and inositol 1, 4, 5-triphosphate receptors in the neurotoxic effects induced by the amyloid-beta peptide. J Neurosci Res 2004; 76: 872-880
163. Dreses-Werringloer U, Lambert JC, Vingtdeux V, Zhao H, Vais H, Siebert A, et al. A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell 2008; 133: 1149-1161
164. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci USA 2003; 100: 10032-10037
165. Guo JL, Lee VM. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 2011; 286: 15317-15331
166. Guo JP, Arai T, Miklossy J, McGeer PL. Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci USA 2006; 103: 1953-1958
167. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006; 52: 831-843
168. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. Beta-Amyloid (1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 2000; 275: 5626-5632
169. Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, et al. The complex PrP(c)-Fyn couples human oligomeric Abeta with pathological tau changes in Alzheimer's disease. J Neurosci 2012; 32: 16857-71a.
170. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, et al. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 2012; 15: 1227-1235
171. Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, Garcia KC, et al. Human LilrB2 is a beta-Amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science 2013; 341: 1399-1404
172. Knowles JK, Rajadas J, Nguyen TV, Yang T, LeMieux MC, Vander Griend L, et al. The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo. J Neurosci 2009; 29: 10627-10637
173. Cisse M, Checler F. Eph receptors: new players in Alzheimer's disease pathogenesis. Neurobiol Dis 2015; 73: 137-149
174. Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 2013; 79: 887-902
175. Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P, et al. Soluble betaamyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci 2005; 25: 11061-11070
176. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007; 27: 2866-2875
177. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004; 304: 448-452
178. Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum Mol Genet 2011; 20: 2495-2509
179. Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci 2015; 18: 794-799